



ANTABIO Announces Appointment of Dr. Erick Lelouche as Chairman of the Board

Labège, France, 19 March 2024

Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, is pleased to announce the appointment of Dr. Erick Lelouche as Chairman of the Board of Directors.

Before joining the Board of Antabio, Erick Lelouche was Chair of the Boehringer Ingelheim Group in France, a position he has held since 2019. Erick is a graduate of the National Veterinary School of Nantes and of the University School of Management of Montpellier. He has held various senior executive positions in large pharmaceutical companies, such as Pfizer and Boehringer Ingelheim. At Boehringer Ingelheim he served as Director of the Animal Health division then as Marketing Director for Human Health where he launched several major products, particularly in cardiology and pulmonology. In January 2017, he became President of Boehringer Ingelheim Animal Health in France and then Chair of the Boehringer Ingelheim Group in France in 2019.

“We are very pleased to welcome Erick Lelouche to the Antabio Board” said Marc Lemonnier, Chief Executive Officer and founder of Antabio. “Erick’s deep industry experience and One Health perspective will be invaluable to Antabio as we continue to develop our life-saving treatments for patients suffering from the consequences of antimicrobial resistance”.

“I am honored to join the Antabio pioneering team led by Marc Lemonnier at the forefront of the fight against antimicrobial resistance” Erick Lelouche said. “I am confident that together, by harnessing our collective expertise, we will make meaningful impact for the benefit of patients suffering from drug-resistant infections worldwide”.

About ANTABIO

Antabio is a clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections as defined by the CDC and WHO’s critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. In November 2023, the Company completed a €25m series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors including BNP Paribas Développement, Relyens Innovation Santé / Turenne Capital, IRDI Capital Investment and Christophe Ricard, the former President of OM Pharma. The company’s lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant *Acinetobacter baumannii* (CRAB) and carbapenem-resistant Enterobacterales (CRE). Antabio’s portfolio also includes the PEi program aimed at developing a groundbreaking, novel class, novel mode of action inhalation treatment of *Pseudomonas aeruginosa* (PA) infections, particularly those affecting patients with chronic pulmonary diseases (such as Bronchiectasis, Cystic Fibrosis and COPD).

Media Contact : Carine Danaire press@antabio.com